课题基金 / 基金详情

Cost-effectiveness of Pharmacogenomic-guided (PGX) Approach to Warfarin Therapy among Patients diagnosed with Atrial Fibrillation: Experimental Evidence from Ontario

药物基因组学指导 (PGX) 方法对诊断为心房颤动的患者进行华法林治疗的成本效益：来自安大略省的实验证据

批准号：

386422

负责人：

Hafeez Aneeka

金额：

$1.27万

依托单位：

University of Western Ontario

依托单位国家：

加拿大

项目类别：

Studentship Programs

财政年份：

2017

资助国家：

加拿大

项目状态：

已结题

起止时间：

2017-12-01 至 2018-12-01

来源：

https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=386422&lang=en

关键词：

Atrial Fibrillation Cost-Effectiveness Personalized Medicine Pharmacogenomic-Guided (Pgx) Care Model Warfarin

项目摘要

项目成果

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Atrial fibrillation (AF) is a condition defined by the presence of irregular rapid heartbeats and commonly treated by an anticoagulant called warfarin to reduce the risk of stroke and embolism. However, warfarin has a narrow therapeutic window and rigorou

期刊论文(0)

专著(0)

科研奖励(0)

会议论文